Stocks · News reference
Nexentis Technologies Subsidiary MitoCareX Bio Narrows Its SLC Transport Protein Candidates To Select Candidate For A Drug Discovery Campaign
As previously disclosed, MitoCareX's broad structural analysis identified a set of SLC transport proteins outside its mitochondrial program that appeared compatible with the MITOLINE® enabled structural modelling.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Nexentis Technologies Unit MitoCareX Bio Launches Its Computational Drug Discovery Infrastructure On Google Cloud Platform
The transition is designed to provide MitoCareX with a secure and flexible computing environment for its computational activities and evolving drug discovery requirements. The infrastructure deployment is expected to
8-K filing — Nexentis Technologies Inc. (NXTS)
Filed: 2026-10-06 AccNo: 0001493152-26-045885 Size: 823 KB Item 1.01: Entry into a Material Definitive Agreement Item 9.01: Financial Statements and Exhibits
Nexentis: MitoCareX Strengthens Its Computational Drug Discovery Capabilities with Appointment of Prof. Dan T. Major to Scientific Advisory Board
Nexentis Technologies' subsidiary MitoCareX Bio Ltd. announced the appointment of Prof. Dan T. Major to its Scientific Advisory Board to strengthen its computational drug discovery capabilities. Prof. Major, a computational chemistry expert from Bar-Ilan University, will advise on in silico drug-discovery approaches and computational methods to support MitoCareX's expansion of internal scientific capabilities and prioritization of discovery programs.